<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229082</url>
  </required_header>
  <id_info>
    <org_study_id>MFDU002</org_study_id>
    <nct_id>NCT04229082</nct_id>
  </id_info>
  <brief_title>Next Generation Probiotics (NGPs) for Metabolic Health</brief_title>
  <official_title>Next Generation Probiotics (NGPs) for Metabolic Health - Metagenomic Analysis to Identify NGP Candidates Correlated With Body Weight or Metabolic Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medfiles Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>4Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danisco</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify differences in the intestinal microbiota by metagenomics analyses between lean
      and obese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2016</start_date>
  <completion_date type="Actual">June 9, 2017</completion_date>
  <primary_completion_date type="Actual">October 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the differences in the intestinal microbiota profile between lean and obese subjects.</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>lean</arm_group_label>
    <description>BMI between 18−25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obese</arm_group_label>
    <description>BMI between 27.5−35</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational</intervention_name>
    <arm_group_label>lean</arm_group_label>
    <arm_group_label>obese</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal, urine, blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        General adult population
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females.

          2. Age between 20 to 50 years.

          3. Obtained his/her informed consent after verbal and written information.

          4. Sufficient general health and orientation for participating in the study as evaluated
             by the study personnel.

          5. Have a high probability for compliance with and completion of the study.

          6. Available for study visits and availability for food

          7. Normal gastrointestinal function.

          8. Willingness to provide faecal, urine and blood samples and keep food diary

        Exclusion Criteria:

        Lactobacillus Rhamnosus GG or reuteri, bifidobacteria enriched products) in the past 6
        weeks. 12. Use of anti-obesity drugs. 13. Active or recent (last 3 months) participation in
        a weight loss program including weight change (increase or loss) of 3 kg during the past
        three months. 14. Special diets e.g. Vegetarian, Vegan, Diets with intention to use certain
        limited food groups only (like paleo diet, egg-grape diet etc.) 15. History of chronic
        active inflammatory disorders. 16. History of bariatric surgery. 17. Regular use of
        non-steroidal anti-inflammatory drugs, corticosteroids, or equivalent immunomodulatory
        drugs. 18. Ongoing or recent (last 3 months) antibiotic treatment. 19. Immunosuppression or
        ongoing therapy causing immunosuppression. 20. Use of vitamin supplementations beyond
        Recommended Daily Intake levels during the previous 2 months and during the study, except
        for vitamin D supplementation up to 20 μg/day.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

